Next-generation sequencing (NGS) offers oncologists the ability to identify actionable targets and select appropriate therapies for some patients. Most patients with metastatic pancreatic ductal adenocarcinoma don’t respond to standard-of-care therapies, so researchers turned to molecular profiling in an effort to optimize therapy by grouping these patients into therapeutically actionable subgroups. Recently published results from this initiative, called Know Your Tumor, demonstrate the feasibility and utility of a comprehensive precision medicine program to both discover actionable findings and improve progression-free survival (PFS) in patients who receive targeted therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“One of the hallmarks of this program is that it was not limited to academic medical centers,” says Davendra Sohal, MD, MPH, Director of Cleveland Clinic Cancer Center’s Clinical Genomics Program. “This study tested the real-world relevance of this approach, to make it accessible to as many patients as possible.”
The Pancreatic Cancer Action Network’s Know Your Tumor initiative, in partnership with Perthera, included tumor samples from 640 patients from 287 academic and community practices in 44 states. A cloud-based tumor board reviewed the results of each patient’s NGS and immunohistochemistry testing and found actionable targets in 50 percent (with 27 percent highly actionable) of patients tested. Commonly altered pathways discovered by testing included AKT/mTOR (19 percent), DNA repair (15 percent) and cell cycle (11 percent). Patients who received targeted therapy based on these results (n = 17) experienced significantly longer PFS, 4.1 months, than patients receiving unmatched therapy (n = 18, PFS 1.9 months; HR, 0.47; 95% CI 0.24-0.94; Padj = 0.03).
“These results, albeit not in a randomized trial, add to the growing evidence that treating patients with biomarker-matched agents increases survival when compared with historical data on standard therapies,” says Dr. Sohal. “We also showed that it’s possible to increase clinical trial enrollment in a population of patients that historically has enrolled at very low rates.” Features of the program designed to engage patients in their results more actively contributed to a 21 percent enrollment rate in applicable clinical trials, versus a 5 percent average across all patients with metastatic pancreatic cancer.
Not all patients in the program chose the targeted treatments suggested in their individual reports. Overall, 63 percent of patients were still placed on standard-of-care regimens. “This could be due to issues with insurance coverage, access to clinical trial sites or reluctance from physicians to try regimens that, while not without evidence of benefit, are not as well-tested as standard therapies,” says Dr. Sohal.
Efforts to inform patients and physicians about the potential benefits of molecular profiling continue, and the initiative continues to expand. “We know that pancreatic cancer should be treated based on an individual patient’s tumor biology,” says Dr. Sohal. “This initiative aims to make that possible.”
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy